In the original article, there was a mistake in Table 1 as published. The studies from Chen et al. and O’Neal et al. were conducted in United States rather than China and UK. The corrected Table 1 appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Table 1
| Author (year) | Country | S | P | I | C | O | Quality score | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Study design | MC/SC | Study period | At-risk patients (participants) | ALI/ARDS definition | Dose and duration of aspirin use | Adjusted confounders | No. of arms(aspirin/non-aspirin) | Reported outcomes | |||
| Boyle et al. (2015)[20] | UK | PS | SC | 12/2010 -07/2012 | ARDS patients | North AmericaEuropean consensus | 75-300 mg/daily | Age, APACHE II score, Coronary artery disease, PaO2/FiO2 ratio, Vasopressor use | 56/146 | ICU mortality; duration of ICU stay; hospital mortality. | 7 |
| Chen et al. (2015)[19] | US | PS | SC | 23/01/2006 -18/02/2012 | Critically ill patients | Berlin definition | 81 mg/d, 325 mg/d | Age, gender, race, sepsis and APACHE II score | 287/862 | Risk of ARDS; risk of sepsis. | 8 |
| Kor et al. (2011)[21] | US | PS | MC | 03/2009 -09/2009 | Patients with at least one major risk factor for ALI | Standard American-European consensus | NA | Age, Sex (male), Admission Source, Diabetes Mellitus, Cirrhosis, Chronic Kidney Disease, Stage V, Congestive Heart Failure, Class IV, Chronic Obstructive Pulmonary Disease, Gastroesophageal Reflux Disease, Immunosuppression, ACE-I/ARB, Statin, Amiodarone | 976/2879 | Development of ARDS; ICU and hospital mortality; ICU and hospital length of stay. | 7 |
| Mazzeffi et al. (2015)[22] | US | RS | SC | 01/07/2008 -30/06/2013 | Patients who had AVRS during a 5-year period | Berlin definition | 81 mg/d during the study period | Age, Cerebral vascular disease, Congestive heart failure, Diabetes mellitus, Dyslipidemia, Dialysis dependent, Male sex, Height, Hypertension, Infectious endocarditis, International normalized ratio, Left ventricular ejection fraction, Peripheral vascular disease, Weigh | 181/194 | Occurrence of ARDS; nadir PaO2/FiO2 ratio | 7 |
| O’Neal et al. (2011)[23] | US | PS | SC | 23/01/2006-01/04/2008 | Critically ill patients | The North American-European consensus | 81 mg or 365 mg daily use | Prehospital statin use, Age, Gender, Current Tobacco Use, Race, APACHE II score | 149/462 | ICU mortality; duration of ICU stay; hospital mortality | 7 |
| Kor et al. (2016)[25] | US | RCT | MC | 02/07/2012- 17/11/2014 | Patients with LIPS ≥ 4 | Berlin definition | 325 mg loading dose followed by 81 mg/d for 7 d | NA | 195/195 | Development of ARDS; ventilator- free days to hospital 28 d; ICU and hospital lengths of stay; 28 d mortality. | 7 |
| Tuinman et al (2012)[24] | Netherlands | PS | SC | NA | Critically ill patients | 2004 consensus definition | 80 mg/d or 100 mg/d for 30 d | Amount of RBCs, FFP, PLTs and propensity score | 109/109 | Incidence of transfusion -related ALI | 8 |
Characteristics of the included studies.
Summary
Keywords
aspirin, acute respiratory distress syndrome, at-risk, systematic review, meta-analysis
Citation
Liang H, Ding X, Li H, Li L and Sun T (2020) Corrigendum: Association Between Prior Aspirin Use and Acute Respiratory Distress Syndrome Incidence in At-Risk Patients: A Systematic Review and Meta-Analysis. Front. Pharmacol. 11:583449. doi: 10.3389/fphar.2020.583449
Received
16 July 2020
Accepted
07 September 2020
Published
30 September 2020
Volume
11 - 2020
Edited and reviewed by
Olayinka Olabode Ogunleye, Lagos State University, Nigeria
Updates
Copyright
© 2020 Liang, Ding, Li, Li and Sun.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tongwen Sun, suntongwen@163.com
†These authors have contributed equally to this work
This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.